GN-CORPORATION
Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical resection of malignant pancreatic tumor, which was presented at the ASCO® Breakthrough meeting in Yokohama, Japan. IgA and CD209, markers of immunity enhanced while CA19-9, the marker of pancreatic cancer and CD44, that of cancer recurrence and severity, significantly reduced in patients who had Nichi BRITE, compared to the control group in the study by gastro-enterology surgeons and nutritional support team of Chikamori Hospital, Kochi, Japan. Importantly, the mean survival improved after Nichi BRITE administration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807498226/en/
The Nichi BRITE Beta 1,3-1,6 Glucan is produced as an exo-polysaccharide by Aureobasidium Pullulans in a GMP certified facility in Japan and is water soluble. The subjects of Nichi BRITE group in the study were given 250mg Beta glucan as an active ingredient per day for 22 days as an adjuvant, while control group had a placebo instead; both groups were given standard of care treatment. The quantity consumed during the study by each patient is equivalent to four boxes of Nichi BRITE, which comes in a box of 24 sachets, 1.5-gram granule as content with 63 mg active beta glucan as ingredient per sachet. Oral administration was undertaken when possible, and when it was not possible, administration was through feeding gastrostomy or nasogastric tube. No adverse reactions were observed. The efficacy in terms of immune enhancement, cancer biomarker reduction and longer mean survival were reported with Nichi Brite as an adjuvant. (Graphic: Business Wire)
Pancreatic cancer has a very poor prognosis. Earlier data of Nichi BRITE allergen-free food supplement on safety and efficacy in improving the immune system, decreasing tumor size in animal models and improving NK cell cytotoxicity in healthy volunteers, elderly people and cancer patients formed the basis of this clinical study. In the study, Nichi BRITE beta glucans were administered from one-day prior to the surgery, until 21st post-operative day, either orally or through feeding gastrostomy. There were no adverse reactions with Nichi BRITE and the outcome was very encouraging, said Dr Akira Tsukada, Chief Hepato-biliary pancreatic surgeon.
The immune enhancement parameters increased in the Nichi BRITE consumed group compared to the control group. IgA level improved, which is the first line of defense against infections, and CD209 improved significantly, which represents monocyte derived dendritic cells that present foreign antigens for destruction by the immune system. Such immune enhancement, the researchers consider, has led to decline in CD44 cancer stem cells that cause metastases, reduction of pancreatic cancer marker CA19-9 and prolongation of lifespan evident by longer mean survival, confirming the multipronged advantages of Nichi BRITE.
While thanking Dr. Masanori Chikamori, Emeritus chairman for his initiatives, and Prof. Nobunao Ikewaki of Kyushu University of Medical Science who undertook the laboratory investigations, they recommend consideration of Nichi BRITE as a routine onco-nutrition supplement to be included in the clinical nutrition guidelines for patients undergoing surgical procedure for cancer and other conditions.
Nichi BRITE is not a drug or remedy to any illness and doesn’t carry any therapeutic claims. Research findings are for the understanding of healthcare professional and not to be construed as medical advice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807498226/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2026 Japan Prize Laureates Announced21.1.2026 06:00:00 CET | Press release
The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. (JST) on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication, and 185 nominations for the field of Life Scie
Ant Group’s AI Health Service AQ Upgrades PC Platform with DeepSearch for Evidence-Based Clinical Decision Support21.1.2026 04:12:00 CET | Press release
Ant Group today announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for clinicians, a new capability designed to support evidence-based clinical decision-making. The service is available free of charge to clinicians and medical students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120591991/en/ AQ’s PC platform provides medical professionals with two core capabilities: Health Q&A and DeepSearch. It supports medical literature search, clinical practice, and research, helping reduce clinicians’ day-to-day workload while improving access to high-quality medical information. To ensure accuracy and reliability, AQ rigorously curates its sources based on recognized levels of evidence. The platform integrates more than 36 million high-quality Chinese and international medical publications, making its clinical decision support closely aligned with real-world practice. Deep
NIKE, Inc. Announces New Geography Leadership Appointments20.1.2026 22:15:00 CET | Press release
NIKE, Inc. (NYSE: NKE) today shared the following note with teammates regarding changes to its Senior Leadership Team: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120575539/en/ César Garcia, VP/GM Nike Europe, Middle East and Africa (EMEA) To: Lst-Global From: EHill Subject: Leadership Announcements Team, In recent months, the Senior Leadership Team has benefited from having our Geography VP/GMs at the table helping us move faster and bringing us closer to athletes* in both countries and marketplaces around the world. As we continue to drive our Win Now actions and stand up our Sport Offense, I’d like to share several important leadership changes across three of our Geo VP/GM roles. EMEA Carl Grebert, a true legend on our team, has decided to retire after nearly 30 years of service and leadership across global, country and geography roles across the company. Carl shared his thinking with me some time ago, and I’m deepl
Xsolla Expands Payment Coverage in Portugal With MB Way, a Leading Mobile Wallet Trusted by 6 Million Customers, to Unlock New Growth Opportunities for Game Developers20.1.2026 16:41:00 CET | Press release
Empowering Portuguese players with Seamless, Localized Payment Options for a Smoother and More Trusted Gaming Experience Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced the expansion of its payments solution in Portugal with the addition of MB Way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120938007/en/ Graphic: Xsolla Portugal is a leader in digital transformation, with nearly 90% of its population online, high smartphone usage, and a strong adoption of mobile banking. Trusted by 6 million people, connected to 11 million cards, supported by 28 banks, and driving 496 million transactions in 2024, MB Way provides 95% market coverage, allowing most bank customers to use the service. MB Way is the leading mobile wallet in Portugal, with an estimated market share of 34%-45% of all e-commerce transactions locally. By adding MB Way as a payment meth
Balena Secures Strategic Growth Investment to Accelerate Edge AI and IoT Fleet Management20.1.2026 15:14:00 CET | Press release
New partnership fuels product innovation and reinforces Balena’s position as the leading hardware-agnostic platform dedicated to the security and long-term stability of device fleets Balena, the leading platform for deploying, managing, and scaling fleets of edge computing and AI devices, today announced a strategic growth investment from LoneTree Capital (“LoneTree”), a New York-based growth capital firm. The partnership will accelerate Balena’s product innovation with a focus on Edge AI workloads and security features to meet evolving compliance needs, while expanding resources for customer success and global fleet support. Founded in 2011, Balena enables customers to leverage the ever-increasing power of technology to solve real-world problems by providing software to manage the full lifecycle of edge computing devices. The platform abstracts away infrastructure complexity, handling critical tasks like secure Over-The-Air (OTA) updates so engineering teams can focus on their core pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom